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Anoikis is a fundamental cellular process for maintaining tissue homeostasis. Resistance to anoikis is a hallmark of oncogenic
epithelial–mesenchymal transition and is a pre-requisite for metastasis. Previous studies have revealed that the heavily glycosylated
mucin protein MUC1, which is overexpressed in all types of epithelial cancer cells, prevents anoikis initiation in response to loss of
adhesion. This effect of MUC1 is largely attributed to its extracellular domain that provides cell surface anoikis-initiating molecules
with a ‘homing’ microenvironment. The present study investigated the inﬂuence of O-glycosylation on MUC1 extracellular domain
on MUC1-mediated cell resistance to anoikis. It shows that stable suppression of the Core 1Gal-transferase (C1GT) by shRNA
substantially reduces O-glycosylation in MUC1-positively transfected human colon cancer HCT116 cells and in high MUC1-
expressing SW620 cells. Suppression of C1GT signiﬁcantly increased anoikis of the MUC1-positive, but not MUC1-negative, cells in
response to suspended culture. This effect was shown to be associated with increased ligand accessibility to cell surface anoikis-
initiating molecules such as E-cadherin, integrinβ1 and Fas. These results indicate that the extensive O-glycosylation on MUC1
extracellular domain contributes to MUC1-mediated cell resistance to anoikis by facilitating MUC1-mediated prohibition of
activation of the cell surface anoikis-initiating molecules in response to loss of cell adhesion. This provides insight into the
molecular mechanism of anoikis regulation and highlights the importance of cellular glycosylation in cancer progression and
metastasis.
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INTRODUCTION
Anoikis is a special apoptotic process that occurs in cells in
response to loss of adhesion to the extracellular matrix.1,2 It is a
fundamental cellular process for maintaining tissue homeostasis
by removing displaced epithelial/endothelial cells and thus
preventing them from seeding to inappropriate sites.
Anoikis initiation starts from the cell surface through activation
of the cell surface anoikis-initiating molecules such as integrins
and death receptors. Loss of cellular adhesion to the extracellular
matrix induces changes (for example, conformational changes,
oligomerization or ligand ligation) of the cell surface anoikis-
initiating molecules which initiate a series of events leading to
activation of either the caspase-8-mediated extrinsic apoptosis
signalling pathway or the mitochondrial-mediated intrinsic
apoptosis signalling pathway and consequent triggering of
apoptosis.3–5 For example, loss of the cell surface integrin
engagement with the extracellular matrix induces integrin
conformational changes and the formation of oligomers that
trigger inactivation of the pro-survival cell signalling such as those
mediated by FAK and PI3K, leading to activation of the
mitochondrial-mediated apoptosis signalling. Loss of cell–matrix
contact induces ligation of the cell surface death receptors with
their ligands, resulting in release of pre-caspase-8 from death
receptor/FADD complex and subsequent activation of caspase-8-
mediated extrinsic apoptosis signalling pathway. Resistance to
anoikis is a hallmark of oncogenic epithelial–mesenchymal
transition6 and metastasis7 and is a pre-requisite for
metastasis.8,9
MUC1 is a large (MW up to 500 kDa) and heavily glycosylated
transmembrane protein that is expressed exclusively on the apical
side of normal epithelial cells and protrudes up to 10-times further
than other typical cell surface molecules above the cell surface.10 It
consists of a large and heavily glycosylated (up to 50% of the
MUC1 molecular weight) extracellular domain, a transmembrane
region and a short cytoplasmic tail. MUC1 is overexpressed up to
10-fold in epithelial cancer cells,11 where it also becomes
expressed over the entire cell surface.12 Overexpression of
MUC1 is closely associated with high metastatic potential and
poor prognosis in cancer patients13,14 and is a much-studied
therapeutic target in cancer therapy.15
In previous studies we found that overexpression of MUC1
prevents initiation of anoikis of epithelial cancer cells in response
to loss of cell adhesion.16 We showed that this effect of MUC1 is
attributed to both the MUC1 intracellular and extracellular
domains but a predominate inﬂuence comes from the MUC1
extracellular domain. This prevents activation of the cell surface
anoikis-initiating molecules in response to loss of cell adhesion,
possibly by providing them a ‘homing’ microenvironment due to
its large and elongated structure that protrudes over the cell
surface. As the MUC1 extracellular domain is heavily modiﬁed by
O-linked mucin type glycans, we have speculated that these O-
linked sugar chains may play a role in MUC1-mediated cell
resistance to anoikis upon loss of cell adhesion.
This study investigated the role of O-glycosylation on the MUC1
extracellular domain in MUC1-mediated resistance to anoikis. We
used a shRNA strategy to shorten the MUC1 O-glycans by
suppressing the Core 1Gal-transferase (C1GT, T-synthase) activity.
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C1GT is a key glycosyltransferase in the biosynthesis of O-linked
mucin type glycans.17 It is responsible for the formation of the
Core 1 structure (Galβ1,3GalNAcα-, T or TF antigen),18–20 which is
overexpressed by over 90% of cancer cells21 and is a natural
ligand of the galactoside-binding galectins.12,22 The formation of
TF acts as a structural base for further elongation of the sugar
chains to form other Core-1-related complex (for example, Core-2-
associated) glycans.23 Although Core 1 formation is not directly
involved in the biosynthesis of other complex (for example, Core-
4-related) glycans, Core-1-related glycans have been reported to
be the predominate structures of MUC1 O-glycosylation in breast
cancer.24 We show in this study that stable shRNA suppression
C1GT reduces MUC1 O-glycosylation and substantially reduces
MUC1-mediated cell resistance to anoikis in human colon
cancer cells.
RESULTS
Generation of C1GT stable suppression in MUC1-positive and
-negative human colon cancer HCT116 cells
MUC1-positively (HCT116MUC1-F3, F3) and –negatively
(HCT116MUC1-neo, Neo) transfected HCT116 cells were generated
previously16 and their positive and negative MUC1 expression is
also conﬁrmed here (Figure 1a).
To determine the role of MUC1 O-glycosylation on MUC1-
associated cell resistance to anoikis, we ﬁrst generated C1GT
stably suppressed cells using shRNA in both MUC1-positive and –
negative cells. After transfection of the cells with shRNA C1GT or
control shRNA, a number of single-cell colonies were obtained.
Expressions of TF, Tn (N-acetyl-galactosamineα-, GalNAc-α) and
MUC1 in these cells were analysed by lectin/immunoblotting
using TF-binding peanut agglutinin (PNA), N-acetyl-galactosa-
mine-binding Vicia Villosa lectin (VVA) and antibody against the
MUC1 extracellular domain B27.29 and antibody against the MUC1
cytoplasmic domain CT-2. In comparison to the control shRNA
transfected cells (C8, F2) and to the non-transfected cells, ﬁve
single-cell colonies (B7, D5, E7, C6 and E11) from the shRNA C1GT
transfected F3 cells showed various degrees of C1GT suppression
as illustrated by the substantial (from above 400 to ~o300 kDa)
reduction of the MUC1 extracellular domain molecular weight (as
a result of reduced glycosylation) and reduction (45–73%) of TF
expression (PNA binding; Figure 1b). Two of the more C1GT-
suppressed colonies (E7 and B7, 66 and 73% reduction of PNA
binding, respectively) were further analysed for cell surface TF and
Tn expressions (PNA and VVA binding) by ﬂow cytometry
(Figures 1c–e). In comparison to control sh-con F2 cells, shRNA
transfected sh-C1GT B7 and E7 cells showed 73 and 80%,
respectively, reduction of cell surface TF structure. When
compared to the control sh-con C8 cells, cell surface TF expression
was reduced by 64 and 74%, respectively, in the shRNA
transfected sh-C1GT B7 and E7 cells. A 623 and 845% increase
of cell surface Tn structure was seen in sh-C1GT B7 and E7 cells,
respectively, when compared to sh-con F2, and a 559 and 761%
increase when compared to sh- con C8, respectively (Figures 1c
and e). These results show that shRNA C1GT suppression has
substantially reduced MUC1 O-glycans in these cells.
A similar shRNA C1GT approach was applied to the MUC1-
negative Neo cells. A number of single-cell colonies (sh-C1GT1-4)
from the cells treated with shRNA C1GT demonstrated reduction
of TF structure (PNA binding) in comparison to the control shRNA-
treated cells (sh-con1-4) when analysed by PNA blot (Figures 2a
and b), suggesting successful shRNA C1GT suppression. Flow
Figure 1. shRNA C1GT suppression in MUC1-expressing HCT116. MUC1 expression in HCT116 cells stably transfected with MUC1 (HCT116-F3)
or control vector (HCT116-neo) were measured by immunoblotting with antibody B27.29 against the MUC1 extracellular domain (MUC1-ED),
antibody CT2 against the MUC1 cytoplasmic tail/domain (MUC1-CT) or actin (a). MUC1-positive F3 cells were stably transfected with shRNA
C1GT or control shRNA and a number of single-cell colonies were analysed by immunoblotting (b) with antibodies against MUC1 (B27.29 and
CT2) or by biotin-PNA. The cells were also assessed for cell surface TF and Tn expressions by PNA and VVA binding by ﬂow cytometry (c), solid
and dotted lines show the positions of peak PNA binding without and with shRNA C1GT suppression, respectively. Dotted line shifted to the
left or right of the solid line indicates reduction or increase of molecule expression, respectively). The mean ﬂorescence intensity of PNA and
VVA cell surface binding were shown in d and e. Data in d and e are expressed as mean± S.D. ﬂorescent intensity from duplicate
determinations of two experiments, ***Po0.001.
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cytometry analysis also showed reduction of cell surface TF
expression of the shRNA C1GT suppressed cells (Figures 2b and c),
conﬁrming C1GT suppression in these cells. Little change of Tn
expression (VVA binding) was however observed in response to
shRNA C1GT or control shRNA treatment in these cells (Figures 2b
and d).
Suppression of C1GT in MUC1-positive, but not –negative, cells
increases anoikis
We then assessed the anoikis response of these cells to suspended
culture. It was found that in response to 24 h suspended culture,
caspase 3/7 activity in the MUC1-negative neo cells was three
times higher than in the paired MUC1-positive F3 cells (Figures 3a
and b), conﬁrming the role of MUC1 expression on cell resistance
to anoikis as reported previously.16 To the MUC1-positive cells,
shRNA suppression of C1GT (E7 and B7) resulted in higher caspase
3/7 activation in response to suspended culture than the control
shRNA-treated (F2, C2) or non-transfected (F3) cells (Figure 3a). In
the MUC1-negative cells, on the other hand, shRNA suppression of
C1GT (sh-C1GT 3–4 produced no signiﬁcant effect of cell caspase
3/7 activation in response to anoikis culture in comparison to
either the shRNA control (sh-con 1–2) or parent MUC1-negative
cells (Neo; Figure 3b). These results indicate that suppression of
MUC1 Core 1 glycosylation markedly reduces MUC1-mediated
resistance to anoikis.
When Annexin-V cell surface binding was assessed in response
to 24 h suspended culture, the MUC1-positive F3 cells showed
much less Annexin-V binding than the MUC1-negative (Neo) cells
(32 versus 53% late apoptotic cells, respectively; Figure 3c). After
shRNA C1GT suppression, the MUC1-positive cells (B7) showed
28% increase of Annexin-V binding in comparison to the control
transfected shRNA cells (C8) (41 versus 32% late apoptotic cells,
respectively; Figure 3d). On the other hand, suppression of C1GT
(sh-C1GT-1) in the MUC1-negative (Neo) cells only slightly
increased (5%) Annexin-V binding than the control transfected
cells (sh-con-1; 61 versus 58%, respectively; Figure 3e) and the
binding was also broadly similar as the control shRNA-treated
cells. These results conﬁrm the inhibitory role of MUC1 in cell
resistance to anoikis shown previously16 and also support an
active role of MUC1 O-linked sugar chains in MUC1-mediated cell
resistance to anoikis.
Suppression of C1GT increases ligand accessibility/binding to cell
surface anoikis-initiating molecules
Our previous study showed that MUC1-mediated resistance to
anoikis is associated with MUC1 prevention of activation of the cell
surface anoikis-initiating molecules, possibly by physically pre-
venting the interaction of cell surface anoikis-initiating molecules
with their ligands due to the great size of MUC1.16 It was found
here that in comparison to the control shRNA cells (F2 and C8),
antibody binding/accessibility to cell surface E-cadherin, Fas,
integrinβ-1, but not CD44, were all signiﬁcantly increased in the
shRNA C1GT suppressed cells (E7 and B7; Figures 4a and b). SDS-
electrophoresis of cell lysates under denaturing conditions
followed by immunoblotting with the same antibodies showed
no difference in the expression of each of these molecules by
Figure 2. shRNA suppression of C1GT in MUC1-negative HCT116 cells. MUC1-negative (neo) cells were transfected with shRNA C1GT or control
shRNA and a number of single-cell colonies were selected and assessed for TF expression by PNA blotting with biotin-PNA (a). A number of
proteins show reduced TF expression (PNA binding) (arrowed). Cell surface TF and Tn expressions was assessed by biotin-PNA and biotin-VVA
and analysed by ﬂow cytometry (b, solid and dotted lines show the positions of peak PNA binding without and with shRNA C1GT suppression,
respectively. Dotted line shifted to the left or right of the solid line reveals reduction or increase of molecule expression, respectively). The
mean ﬂorescence intensity of PNA and VVA cell surface binding were shown in c and d. Data in c and d are expressed as mean± S.D.
ﬂorescent intensity from duplicate determinations of two experiments, *Po0.05.
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these cells (Figure 4c). This indicates that the difference of
antibody binding to these cell surface molecules shown in
Figure 4a was not due to different expression of these molecules
but likely due to differences in their accessibility. Suppression of
C1GT in the MUC1-positive cells, which shortens the MUC1
O-linked carbohydrate structures, exposes the cell surface
molecules and increases ligand-molecule interactions. This is in
keeping with the role of MUC1 extracellular domain on inhibition
of interaction of cell surface anoikis-initiating molecules with their
ligands in anoikis shown earlier.16
Suppression of C1GT inhibits anoikis induced by exogenous Fas-L
To test the role of MUC1 O-glycosylation on cell surface ligand-
molecule interaction in anoikis induction, we compared the effect
of exogenous addition of Fas-L on caspase-8 activation in cell
response to anoikis culture of shRNA C1GT suppressed MUC1-
positve and –negative cells. Interaction of Fas-L with Fas on the
cell surface is known to induce anoikis/apoptosis through
activation of caspase-8.4,25 It was found that introduction of
exogenous Fas-L signiﬁcantly increased the caspase-8 activity of
the MUC1-negative (Neo) cells but had little inﬂuence on the
MUC1-positive (F3) cells, again supporting the role of MUC1
expression on inhibition of Fas-L-Fas interaction-induced anoikis
as previously reported.16 Suppression of C1GT in F3 cells (E7 and
B7) resulted in signiﬁcant increase of caspase-8 activity in cell
response to anoikis culture, such an effect was however not
observed in the control shRNA transfected cells (F2 and C8;
Figure 5). These results again support a role of MUC1
O-glycosylation in MUC1-mediated anoikis inhibition by partici-
pating in preventing anoikis-initiating molecule interactions with
their ligands on cell surface.
Suppression of C1GT inhibits anoikis in MUC1-positive SW620 cells
To further conﬁrm the role of MUC1 O-glycosylation in MUC1-
mediated cell resistance to anoikis, we stably transfected human
colon cancer SW620 cells, which express high level of MUC1
(Figure 6a), with shRNA C1GT and control shRNA and generated
C1GT stably suppressed cells. A 52% reduction of TF expression
(PNA binding) was seen in the C1GT transfected cells (sh-C1GT) in
comparison to the control transfected cells (sh-con) when
analysed by PNA blotting (Figure 6b). A simultaneous increase
of Tn (GalNAc-α) expression was also seen on the cell surface in
the shRNA C1GT transfectants when analysed by ﬂow cytometry
(Figures 6c and d).
Suppression of C1GT expression (sh-C1GT) in MUC1-highly
expressed SW620 cells resulted in signiﬁcant increase of cell
caspase 3/7 activity in response to 24 suspended culture in
comparison to the non-transfected or control transfected (sh-con)
cells (Figure 7a). The population of Annexin-V/PI-positive cells was
also substantially increased in the sh-C1GT cells in comparison to
the non-transfected or control transfected cells (12.7%, 6.5% and
7.9%, respectively, late apoptotic and necrotic cells; Figure 7b).
These results also support the role of MUC1 O-glycosylation in cell
resistance to anoikis.
Figure 3. Effects of MUC1 expression and of shRNA C1GT suppression on anoikis in MUC1-positive and -negative cells. ShRNA control and
shRNA C1GT transfected cells from MUC1-positive (F3) and negative (neo) cells were cultured in suspension. The cellular caspase 3/7 activities
(a and b) or Annexin-V cell surface binding (c–e) in the transfected (a and d), non-transfected MUC1-positove and -negative cells (c) and
control transfected Neo (e) cells were determined at 0 and 24 h. C1GT suppression increases caspase 3/7 activity in the MUC1-positive cells but
has little inﬂuence in MUC1-negative cells. Data are expressed as mean± S.D. of triplicate determination of three experiments, ***Po0.001. In
c–e, earlier apoptotic (Annexin-V positive and PI negative) cells show at the bottom right and late apoptotic (Annexin-V positive and PI-
positive) cells show at the top right in each of the correlation plots. The numbers in each panel of the correlation plots show the percentage of
the cells in total cell population.
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Suppression of C1GT in SW620 cells increases ligand accessibility
to cell surface anoikis-initiating molecules and increases caspase-8
activity by exogenous Fas-L
Ligand binding/accessibility to cell surface anoikis-initiating
molecules was also compared in the shRNA control and shRNA
C1GT suppressed SW620 cells. Antibody binding to cell surface
E-cadherin, integrinβ1 and Fas, like that in HCT116-F3 cells, was all
increased in the C1GT suppressed cells in comparison to the
control transfectants (Figures 8a and b). Again the expression
levels of these cell surface molecules were the same among the
transfectants (Figure 8c). When the caspase-8 activity was
assessed in response to suspended culture, addition of exogenous
Fas-L increased caspase-8 activity in the C1GT-suppressed but not
the control cells (Figure 8d). Together, these results support the
participation of MUC1 O-glycosylation in MUC1-mediated cell
resistance to anoikis by preventing activation of cell surface
anoikis-initiating molecules.
DISCUSSION
Here we have shown that partial inhibition of O-glycosylation by
stable suppression of C1GT expression signiﬁcantly increased
anoikis of MUC1-positive, but not MUC1-negative, cells in
response to suspended culture. Reduction of the MUC1
O-glycosylation increased ligand/antibody accessibility to cell
surface anoikis-initiating molecules such as E-cadherin, integrinβ1
and Fas and increased caspase-8 activity in response to
exogenous introduction of Fas-L to suspended cells.
C1GT is a key glycosyltransferase in the biosynthesis of O-linked
mucin type glycans, responsible for the formation of the Core
1-related complex O-glycans. Suppression of C1GT blocks Core-1
O-glycosylation and results in increased expression of the short
glycans GalNAcα (Tn) and sialyl-Tn.26 Stable shRNA C1GT
suppression to reduce MUC1 O-glycosylation is supported here
by (1) substantial reduction of the MUC1 extracellular domain
molecular weight size; (2) signiﬁcant reduction of the TF
Figure 4. Effect of shRNA C1GT suppression on antibody accessibility to cell surface anoikis-initiating molecules. The shRNA C1GT transfected
or shRNA control cells from the MUC1- positive F3 cells were incubated with antibodies against E-cadherin, integrinβ1, CD44 or Fas. After
washing and application of FITC-conjugated secondary antibody, the cells were analysed by ﬂow cytometry (a, solid and dotted lines show
the peak positions of control and shRNA C1GT transfected cells, respectively. Dotted line shifted to the left or right of the solid line reveals
reduction or increase of molecule expression). Mean ﬂorescence intensity of the antibody binding are shown in b. Cells were also lysed and
analysed by immunoblotting (c) for the expression of these molecules with the same antibodies as in a. **Po0.01, ***Po0.001.
Figure 5. Effect of MUC1 expression and shRNA C1GT suppression
on Fas-L-induced caspase-8 activation. The MUC1-positive (F3) and
-negative (neo) cells and the shRNA control and shRNA C1GT
transfected cells from MUC1-positive and -negative cells were
cultured in the presence or absence of 100 ng/ml recombinant Fas-L
in suspension for 2 h before the cell caspase-8 activity was
determined by Caspase-8-Glo kit. Data are expressed as percentage
to untreated cells (mean± S.E.M.) of triplicate determination of three
experiments, ***Po0.001.
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disaccharide and (3) signiﬁcant increase of the monosaccharide
glycan Tn (Figure 1). As suppression of C1GT expression will also
affect O-glycosylation on cellular glycoproteins other than MUC1,
we also stably transfected the paired-MUC1-negative cells with
shC1GT. Suppression of C1GT in the paired MUC1-negative cells
reduced glycosylation of a number of cellular proteins (Figure 2).
When the responses of these paired shRNA C1GT cells to
suspended culture were compared, signiﬁcant increase of anoikis
in cell response to suspension culture occurred only in the MUC1-
positive cells but not the MUC1-negative cells. This suggests that
the increased anoikis observed in the MUC1-positive cells is
attributed speciﬁcally to the reduced O-glycosylation of MUC1.
It is noted that elevated expression and activity of N-acetyl-
glucosaminyltransferase-V (Mgat5), which catalyses the biosynth-
esis of β-1–6-linked GlcNAc in N-glycans and hence increases
N-glycan branching,27 has been reported previously to promote
anchorage-independent growth and inhibit anoikis in two
hepatoma cell lines.28 Although N-glycans make only a small
contribution to the overall glycosylation of mucin proteins like
MUC1, their inﬂuence in the hepatoma cells is broadly in
agreement with a role of glycosylation in anoikis shown in
this study.
One of the very early events in anoikis initiation occurs on the
cell surface through activation of the cell surface anoikis-initiating
molecules through either conformation change, oligomerization
Figure 6. shRNA suppression of C1GT in human colon cancer SW620 cells. SW620 cells express very high level of MUC1 as determined by
B27.29 anti-MUC1 antibody followed by analysis with ﬂow cytometry (a). SW620 cells were transfected with shRNA C1GT or control shRNA and
several stably transfected colonies were analysed by immune/PNA blotting with B27.29 antibody against the MUC1 extracellular domain
(MUC1-ED) and CT-2 antibody against the MUC1 cytoplasmic tail/domain (MUC1-CT) and biotin-PNA (b). The cells were also analysed for cell
surface TF and Tn expressions by biotin-PNA and biotin-VVA followed by ﬂow cytometry (c). The mean ﬂorescence intensity of PNA and VVA
binding in c were shown in d. Data are expressed as mean± S.D. of ﬂorescent intensity from duplicate determinations of 2 experiments,
*Po0.05.
Figure 7. Effects of shRNA C1GT suppression on anoikis in SW620 cells. The shRNA control and shRNA C1GT transfected or non-transfected
SW620 cells were cultured in suspension and the cellular caspase 3/7 activity was determined after 24 h (a). Annexin-V cell surface binding
were determined at 0 and 24 h (b). Caspase 3/7 activity is presented as mean± S.E.M. of triplicate determination of three experiments.
*Po0.05.
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or ligation with ligands.3–5 Ligand/antibody accessibility to the cell
surface anoikis-initiating molecules such as integrin, E-cadherin
and Fas is shown in this study to be substantially increased in the
MUC1-positive cells after suppression of the MUC1 O-glycosylation
through C1GT suppression. Caspase-8 activation in suspension
culture in response to exogenous introduction of Fas-L is also
signiﬁcantly increased in the MUC1-positive but not MUC1-
negative cells after C1GT suppression.
Thus, the extensive O-glycosylation of the MUC1 extracellular
domain contributes to resistance to anoikis by preventing
activation of cell surface anoikis-initiating molecules. This provides
further insight into the molecular mechanisms of anoikis
regulation and highlights the importance of cellular glycosylation
in cancer progression and metastasis.
MATERIALS AND METHODS
Materials
The Caspase 3/7 Glo kits and Caspase-8 Glo kits were obtained from
Promega (Southampton, UK). Recombinant Fas-L was from PeproTech
(London, UK). Antibodies against CD44 (BBA10), integrinβ1 (MAB17782),
E-cadherin (MAB1838), Fas (AF2267) and Fas-L (AF126) were from R&D
Systems (Abingdon, UK). FITC-Annexin-V/PI apoptosis detection kit was
from Cambridge Biosciences (Cambridge, UK). Biotinylated peanut
agglutinin (PNA) and biotinylated Vicia Villosa Lectin (VVA) were purchased
from Vector Laboratories, (Peterborough, UK). FITC-conjugated anti-mouse
antibody (115-095-146) was purchased from Jackson Immunoresearch
Labs, West Grove, PA, USA). Chemiluminescence detection kits were from
Thermo Scientiﬁc, (Rockford, IL, USA). Metafectene was from Biontex
Laboratories (München, Germany). B27.29 anti-MUC1 antibody was kindly
provided by Dr Mark Reddish (Biomira, Edmonton, Canada) and CT2 anti-
MUC1 antibody was kindly provided by Prof Sandra Gendler (Mayo Clinic,
AR, USA). ShRNA plasmid DNA for Core 1Gal-transferase (SHCLND-
NM_020156-C1GALT, TRCN0000289384), control shRNA (SHC002v) and
Non-enzymatic cell dissociation solution (NECDS) were from Sigma Aldrich
(Dorset, UK)
Cells
The MUC1-negative human colon cancer HCT116 and MUC1-positive
SW620 cells were obtained from European Collection of Cell Culture
(Salisbury, UK) and were cultured in McCoy’s5A medium. The cell lines
were last authenticated by DNA proﬁling (DNA Diagnostics Centre,
London, UK) in 2014. MUC1-expressiong HCT116MUC1-F3 and MUC1-
negative HCT116MUC1-neo cells were obtained by stable transfection of
HCT116 cells with MUC1-expressing or control vectors as described
previously.16
shRNA C1GT transfection
HCT116 cells were seeded in McCoy’s 5A media for 24 h until 60–70%
conﬂuent. ShRNA for C1GT1 or control shRNA (100 ng) was pre-mixed in
1 : 4 ratio with Metafectin transfection reagent in serum-free and
antibiotic-free McCoy’s 5A media for 30 min before addition to the cells
in antibiotic-free and serum-containing medium in 96-well plate. After 6 h
culture at 37 °C, the culture media was replaced with selection media
containing 10% serum and 0.5 μg/ml puromycin for 72 h. The surviving
Figure 8. Effect of shRNA C1GT suppression increases antibody accessibility to cell surface anoikis-initiating molecules and enhances Fas-L-
induced caspase-8 activity in SW620 cells. shRNA C1GT transfected or shRNA control transfected SW620 cells were incubated with antibodies
against E-cadherin, integrinβ1, CD44 or Fas. After application of FITC-conjugated secondary antibody, the cells were analysed by ﬂow
cytometry (a, solid and dotted lines show the peak positions of control and shRNA C1GT transfected cells, respectively. Dotted line shifted to
the left or right of the solid line reveals reduction or increase of molecule expression). Mean (± S.D.) ﬂorescence intensity of the antibody
bindings are shown in b. Cells were also lysed and analysed for the expression of these molecules by immunoblotting with the same
antibodies (c). In d, the shRNA control and shRNA C1GT transfected SW620 cells were cultured in the presence or absence of 100 ng/ml
recombinant Fas-L in suspension and the cell caspase-8 activity was determined after 2 h by Caspase-8-Glo kit. Data are expressed as
mean± S.E.M. of triplicate determination of three experiments, ***Po0.001.
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cells were released by trypsin, suspended in very low cell density and
seeded into 96-well plates. Wells containing one cell were identiﬁed under
microscope and allowed to proliferated before they were selected and
analysed for TF, Tn or MUC1 expression by lectin/immune blotting and/or
ﬂow cytometry
Immunoblotting
Cell lysates were separated by SDS-PAGE and transferred to nitrocellulose
membrane. The membrane was incubated with biotinylated TF-binding
PNA (2 μg/ml), Tn-binding VVA (2 μg/ml) or antibodies against MUC1
extracellular domain B27.29 (1 μg/ml), MUC1 intracellular domain CT-2
(2 μg/ml), E-cadherin (2 μg/ml), CD44 (2 μg/ml), integrinβ1 (2 μg/ml) or Fas
(2 μg/ml) for 16 h at 4 °C. These blots were washed 3 times with 0.05%
Tween-20 in PBS before incubated with perioxidase-avidin (1 : 5000) and
peroxidase-conjugated secondary antibody (1 : 3000) for 1 h. After six
washes with 0.05% Tween-20 in PBS, the blots were developed using
chemiluminescence Super Signal kit and visualised with Molecular Imager
Gel Doc XR system (Biorad). The blots were striped by stripping buffer
(62.5 mM Tris-HCl pH 6.7, 100 mM β-mercaptoethanol, 2% SDS) and
re-probed by anti-actin antibody (1 : 3000) for protein loading.
Assessments of cell anoikis
The assessments were conducted in cell suspension culture in poly-2-
hydroxyethyl methacrylate (poly-HEMA)-coated plates as described
previously.16 Brieﬂy, 96- or 6-well plates were coated three times with
10 mg/ml poly-HEMA in 95% ethanol overnight. Cells were released by
NECDS from the culture ﬂasks, washed with PBS, resuspended to 5 × 105
cells/ml in serum-free DMEM containing 0.5 mg/ml BSA and applied to the
poly-HEMA-coated plates for various times at 37 °C. The cells were
collected and the apoptotic (anoikis) cells were then measured either by
FITC-Annexin-V/PI apoptosis detection kit with ﬂow cytometry, or by the
Caspase-Glo3/7 Assay kit according to the manufacturer’s instructions
Flow cytometry to assess antibody binding to cell surface
molecules
Cells were released from the culture plates by NECDS and ﬁxed
immediately with 2% paraformaldehyde for 15 min at room temperature.
After washing with PBS, the cells were incubated with 5% goat serum in
PBS for 30 min. The cells were re-suspended at 5 × 105 cells/ml in 1% goat
serum in PBS and incubated with biotin-PNA, biotin-VVA (2 μg/ml)
or antibodies against MUC1 extracellular domain B27.29 (1 μg/ml),
MUC1 intracellular domain CT-2 (0.5 μg/ml), E-cadherin (0.5 μg/ml), CD44
(0.5 μg/ml), integrinβ1 (0.5 μg/ml), Fas (0.5 μg/ml) or control mouse IgG on
a rotation platform for 1 h at room temperature. After three washes with
PBS, FITC- Avidin (1 : 500) or FITC-conjugated secondary antibody (1 : 500
in 1% goat serum in PBS) was applied for 1 h. The cells were washed three
times with PBS before analysis by ﬂow cytometry (BD FACS Canto II).
Effect of exogenous Fas-L on caspase-8 activation
The cells were released by NECDS and seeded at 2 × 105cells/ml in serum-
free DMEM to poly-HEMA-coated 96-well plates with or without
introduction of 100 ng/ml Fas-L for 0 and 2 h before the cellular
caspase-8 activity was measured by Caspase-8-Glo Assay kit according to
the manufacturer’s instruction.
Statistical analysis
Unpaired t-test for single comparison, one-way analysis of variance
(ANOVA) followed by Bonferroni correction for multiple comparisons
(Sigmaplot v12 for Windows, Systat Software Inc, London, UK) were used
where appropriate. Differences were considered signiﬁcant when Po0.05.
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